InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
InspireMD (NSPR) received FDA approval for its CGuard Prime TransCarotid Stent System for transcarotid artery revascularization (TCAR) procedures. The indication covers patients at high surgical risk who meet labeling criteria and requires use with a specified embolic protection system.
The supporting CGUARDIANS II single-arm U.S. trial enrolled 50 pivotal patients across 11 sites. It reported 100% acute device success, no deaths, strokes, myocardial infarctions or stent thrombosis at 30 days, and complete stent patency in evaluable subjects. InspireMD estimates the approval doubles the platform’s U.S. addressable market. The system can enter the TCAR market independently of its investigational SwitchGuard neuroprotection device, which is being evaluated in the enrolling CGUARDIANS III pivotal trial. SwitchGuard remains subject to FDA clearance and is not available for U.S. sale.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointFDA approval extends CGuard Prime to TCAR procedures in the United States.
- Minor point100% acute device success was reported in the CGUARDIANS II pivotal trial.
- Minor pointNo deaths, strokes, myocardial infarctions or stent thrombosis were reported at 30 days in CGUARDIANS II.
- Minor pointComplete stent patency, meaning open stents, was observed in evaluable CGUARDIANS II subjects.
- Minor pointExisting FDA-cleared neuroprotection enables TCAR market entry independently of SwitchGuard development.
- Minor point. Forward-looking: it has not happened yet and may not happen.CGUARDIANS III is enrolling to evaluate SwitchGuard, which the company expects to complement CGuard Prime if cleared.
Negative
- Minor pointApproved use is restricted to qualifying high-surgical-risk patients and requires a labeling-specified embolic protection system.
- Minor pointDevice risks include stroke, death, myocardial infarction, stent thrombosis or occlusion, vessel dissection and access-site complications.
- Minor pointSwitchGuard remains investigational, requires FDA clearance and is not available for sale in the United States.
News Explained
FDA approval now allows U.S. physicians to use CGuard Prime in TCAR, addressing more than 35,000 annual procedures; the company estimates TCAR and CAS together total approximately 75,000 annually.
Details
Market Reaction – NSPR
On Nov 12, the day this news came out, the latest delayed price for NSPR is 3.75% below the previous close. Argus tracked a peak move of +19.8% during the session. Our momentum scanner has recorded 22 alerts for this stock so far that day. The latest delayed price is $0.77.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Acute device success
- 100%
- CGUARDIANS II at 30 days
- Reported major adverse events
- Zero deaths, strokes, myocardial infarctions or stent thrombosis
- CGUARDIANS II at 30 days
- Pivotal patients
- 50 patients
- CGUARDIANS II
- Annual TCAR procedures
- Over 35,000 procedures
- United States
- Annual carotid stenting procedures
- Approximately 75,000 procedures
- TCAR and CAS combined in the United States; based on Company estimates
Previous Fda approval Reports
-
Initial CGuard Prime carotid-stent approval covered stroke prevention; current approval adds TCAR use.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pma regulatory
stent thrombosis medical
nitinol technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR procedures annually –
- Approval supported by CGUARDIANS II pivotal trial data, which demonstrated
MIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s Premarket Approval (“PMA”) Supplement for the CGuard® Prime TransCarotid Stent System for use in transcarotid artery revascularization (“TCAR”) procedures.
The approval allows physicians in the U.S. to use the CGuard® Prime TransCarotid Stent System, which features an 80 cm delivery system, in transcarotid artery revascularization ("TCAR") procedures when used in conjunction with an embolic protection system specified in the labeling. This gives physicians performing TCAR procedures access to the CGuard Prime stent and its proprietary MicroNet™ technology, a permanent protective micromesh that covers the self-expanding nitinol stent.
“Today’s approval is a major milestone for InspireMD and for the physicians and patients who may benefit from TCAR as a treatment option for carotid artery disease,” said Marvin Slosman, Chief Executive Officer of InspireMD. “This approval extends our CGuard implant to TCAR procedures and is expected to provide a strong near-term growth driver for InspireMD. We believe InspireMD is the first and only company to approach carotid revascularization and stroke prevention with both CAS and TCAR delivery options and an implant-first mission, and we view this TCAR approval as an incredibly important step in advancing our leadership in this field. We look forward to providing patients and physicians with this next-generation stent, which we believe delivers unmatched clinical results.”
The approval of the CGuard® Prime TransCarotid Stent System is supported by data from the Company’s CGUARDIANS II pivotal trial. This prospective, multicenter, single-arm U.S. study enrolled 50 pivotal patients across 11 investigational sites and evaluated the CGuard® Prime TransCarotid Stent System platform with TCAR using the FDA-cleared ENROUTE Transcarotid Neuroprotection System (“NPS”) in a high-surgical-risk population. At 30 days, the study achieved
“TCAR has become an increasingly important technique for carotid revascularization in the U.S., and we believe the availability of CGuard Prime for TCAR gives physicians a differentiated stent option designed around sustained embolic protection,” said Patrick J. Geraghty, M.D., Professor of Surgery and Radiology at Washington University School of Medicine in St. Louis and co-lead investigator of the CGUARDIANS II study. “The ability to combine CGuard’s MicroNet technology with transcarotid access and existing flow-reversal neuroprotection provides physicians with an important new option for treating patients with carotid artery disease.”
With more than 35,000 TCAR procedures performed annually in the United States, the approved TCAR indication doubles the CGuard Prime platform’s total addressable market by extending its use beyond CAS procedures. Together, TCAR and CAS represent approximately 75,000 annual carotid stenting procedures in the United States, based on Company estimates.
The approval also represents an important step in InspireMD’s broader TCAR strategy. Initially, the CGuard® Prime TransCarotid Stent System can be used in TCAR procedures with an existing FDA-cleared embolic protection system as specified in the labeling. The Company has developed a full suite of TCAR platform devices including SwitchGuard, its next generation transcarotid NPS, which is being evaluated in the CGUARDIANS III pivotal trial that is currently enrolling. If cleared by the FDA, SwitchGuard is expected to complement the CGuard® Prime TransCarotid Stent System and provide InspireMD with a fully integrated proprietary carotid stent and neuroprotection platform for TCAR procedures, along with a proprietary micro puncture access kit expanding the Company’s opportunity to capture value across the full TCAR procedure.
Indication for Use
The CGuard® Prime TransCarotid Stent System, when used in conjunction with an embolic protection system specified in the labeling, is indicated for improving carotid luminal diameter in patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization and meet the criteria specified in the labeling. Use of the device carries risks, including stroke, death, myocardial infarction, stent thrombosis or occlusion, vessel dissection and access-site complications. Rx only. Refer to the Instructions for Use for complete indications, contraindications, warnings, precautions and potential adverse events.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is listed on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. In particular, forward-looking statements in this press release include the anticipated commercial launch and timing of sales of the CGuard Prime 80 cm stent system for TCAR procedures, the Company’s estimates of the size of the TCAR and CAS markets and its addressable market, the Company’s expectations regarding enhancements to the CGuard Prime 135 cm delivery system, the Company's expectations regarding the CGUARDIANS III pivotal trial and potential FDA clearance of SwitchGuard; the Company's ability to compete effectively in the carotid stenting market with both TCAR and CAS delivery systems and increase adoption of its products; expectations regarding market penetration, commercialization, revenue growth and future operating performance; and the Company's strategic priorities, growth plans and future business prospects. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with the voluntary U.S. recall of the CGuard Prime 135 cm delivery system, including current and future costs associated with the recall, including refunds or inventory write-off costs and other remediation costs, loss of sales and customers due to the recall or otherwise, our ability to effectively implement enhancements to CGuard Prime 135 cm delivery system, potential actions by regulators or other governmental entities associated with the recall, potential claims and lawsuits by customers and patients, including class action product liability lawsuits, other operational impacts and consequences of the recall, such as business disruption and distraction of management and other key employees; the Company’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of its liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; the Company’s need to raise additional capital to meet its business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute out stockholders’ ownership interests; the clinical development, commercialization and market acceptance of the Company’s products; whether the clinical trial results for the Company’s products will be predictive of real-world results; an inability to secure and maintain regulatory approvals for the sale of the Company’s products; negative clinical trial results or lengthy product delays in key markets; the Company’s ability to maintain compliance with the Nasdaq listing standards; the Company’s ability to generate significant revenues from its products; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing, including any unexpected costs or delays in the ongoing commercial launch of its products; the Company’s dependence on a single manufacturing facility and its ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from the Company’s current and planned clinical trials may not be sufficient to demonstrate that its technology is an attractive alternative to other procedures and products; intense competition in the Company’s industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than it does; entry of new competitors and products and potential technological obsolescence of the Company’s products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with the Company’s research and products and potential product liability claims; product malfunctions; price increases for supplies and components; whether access to the Company’s products is achieved in a commercially viable manner and whether its products receive adequate reimbursement by governmental and other third-party payers; the Company’s efforts to successfully obtain and maintain intellectual property protection covering its products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that the Company conducts business in multiple foreign jurisdictions, exposing it to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; security, political and economic instability in the Middle East that could harm the Company’s business, including due to the current security situation in Israel; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; and changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements and the impact of such policies on the Company, its customers and suppliers, and the global economic environment. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Jeff Warren
LifeSci Advisors
jwarren@lifesciadvisors.com
investor-relations@inspiremd.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did the FDA approve for InspireMD’s CGuard Prime TCAR system?
The FDA approved CGuard Prime TransCarotid Stent System for TCAR procedures with an embolic protection system specified in its labeling. The indication covers patients requiring carotid revascularization who are at high risk for adverse events from carotid endarterectomy and meet the labeling criteria.
What were InspireMD’s CGUARDIANS II trial results?
CGUARDIANS II reported 100% acute device success and no deaths, strokes, myocardial infarctions or stent thrombosis at 30 days. The single-arm U.S. study enrolled 50 pivotal patients across 11 sites, with complete stent patency observed in evaluable subjects.